ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3254)	2/26/2014 4:43:36 PM
From: jaybe	Read Replies (1) of 4474

True, for TKIs "pan" means point mutations with binding to active/inactive conformation... I threw in the alternate pathway bit as I believe the future of TKI's as monotherapies will be dual or triple modes of action, similar to '113. I still think '113s moderate activity in EGFRm contributes to duration of response. RON was just a dual action suggestion for MET, could just as well be a key pathway like PI3K. Why the hesitation on MET? I see literature dating back to 80's establishing it as oncogenic driver, albeit in subsets of cancers. Regarding GIST, HB at RBC conf. just stated a front or second line trial will be considered for Pona after ASCO data presentation. I just don't see how announcing a better c-Kit inhibitor in the same year as Pona begins pivotal trial for same indication will rebuild excitement for shareholders or new investors. By the way I thought I would share my cheat sheet for possible candidates. See any missing? nature.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next